Dan Lyne

Executive Vice President

Photo of dan-lyne

Professional Experience

Find Your Perfect Space

Search Properties

Associated Office


321 N. Clark Street
Suite 3400
Chicago, IL 60654

Get Directions

Dan Lyne is an Executive Vice President on the Advisory & Transaction Services team for CBRE. He holds leadership positions for both the Global Health & Life Sciences Practice, as well as the Global Technology & Media Practice. Dan’s career has long focused on the interdependence of life science disciplines with advanced technologies and data analytics.

A well-regarded leader throughout the Chicago business community, Dan represents clients both large and small on complex real estate transactions. Dan is also a senior advisor on public/private client engagements and manages portfolio company services for several notable venture capital and private equity funds. Through his career, he has advised and led transactions for a wide range of both tenants and investors/developers including: 

  • Novartis Gene Therapies
  • Xeris Pharmaceuticals
  • AveXis
  • Baird Venture Capital 
  • Portal Innovations 
  • Builder’s Vision & S2G Ventures
  • The American Medical Association
  • Motorola Solutions
  • Lightbank
  • Horizon Therapeutics
  • Soli Organics
  • P33
  • PayPal
  • Whirlpool
  • SMS-Assist
  • Assertio
  • Spotify USA
  • DocuSign
  • The State of Illinois
  • The University of Chicago
  • Trammell Crow Company
  • Ventas
  • Wexford Life Sciences
  • Beacon Capital Partners
  • Aptinyx

As it is his passion, Dan has focused much of his career on addressing talent attraction and corporate culture via the need for transformational and world-class creative space and R&D environments.

Dan is also the co-founder of "1871" – a 170,000 square foot co-working center for digital startups located in Chicago’s famed Merchandise Mart. Two years later, Dan was on the
founding team that launched MATTER, a 25,000 square foot co-working venture dedicated to entrepreneurs focused on healthcare and life sciences innovation.